Table 4 Effects of ZSCAN4 expression and clinicopathological parameters on prognosis in urinary bladder urothelial carcinoma

Gender

Male

216

41

0.4446

–

–

–

60

0.2720

–

–

–

Female

79

11

–

–

–

16

–

–

–

Age (years)

 < 65

121

17

0.1136

–

–

–

31

0.6875

–

–

–

 ≥ 65

174

35

–

–

–

45

–

–

–

Primary tumor (T)

Ta

84

1

 < 0.0001*

1

–

 < 0.001*

4

 < 0.0001*

1

–

0.002*

T1

88

9

6.413

0.678–60.682

23

5.222

1.508–18.089

T2–T4

123

42

25.816

2.794–238.553

49

7.591

2.179–26.449

Nodal status (N)

Negative (N0)

266

41

0.0002*

1

–

0.827

61

 < 0.0001*

1

–

0.103

Positive (N1–N2)

29

11

1.083

0.530–2.215

15

1.674

0.901–3.109

Histological grade

Low grade

56

2

0.0013*

1

–

0.823

5

0.0007*

1

–

0.803

High grade

239

50

0.836

0.174–4.021

71

1.143

0.488–1.592

Vascular invasion

Absent

246

37

0.0024*

1

–

0.089

54

0.0001*

1

–

0.676

Present

49

15

0.553

0.279–1.095

22

0.882

0.601–1.929

Perineural invasion

Absent

275

44

0.0001*

1

–

0.023*

66

0.0007*

1

–

0.103

Present

20

8

2.630

1.142–6.058

10

1.854

0.882–3.899

Mitotic rate (per 10 high power fields)

 < 10

139

12

 < 0.0001*

1

–

0.003*

23

 < 0.0001*

1

–

0.006*

 >  = 10

156

40

2.734

1.401–5.335

53

2.051

1.223–3.438

ZSCAN4 expression

High

147

13

0.0001*

1

–

0.003*

26

 < 0.0001*

1

–

0.046*

Low

148

39

2.661

1.382–5.123

50

1.669

1.010–2.759